Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective of this study is to evaluate whether treatment with nesiritide improves patient outcomes (as measured by reduction in the composite of HF rehospitalization and all-cause mortality through 30 days after randomization [Day 30]) or HF symptoms (as measured by subject self assessed Likert dyspnea scale at 6 hours and 24 hours after study drug initiation) compared with placebo when each is administered in addition to other standard therapies in patients with ADHF.
Critère d'inclusion
- Acute decompensated heart failure